uniQure N.V. (QURE) and Calithera Biosciences Inc. (NASDAQ:CALA) Comparing side by side

Both uniQure N.V. (NASDAQ:QURE) and Calithera Biosciences Inc. (NASDAQ:CALA) are each other’s competitor in the Biotechnology industry. Thus the compare of their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
uniQure N.V. 11.28M 191.71 83.30M -2.69 0.00
Calithera Biosciences Inc. 22.25M 11.38 54.63M -1.28 0.00

Table 1 demonstrates uniQure N.V. and Calithera Biosciences Inc.’s gross revenue, earnings per share and valuation.


Table 2 has uniQure N.V. and Calithera Biosciences Inc.’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
uniQure N.V. -738.48% -58.5% -35.9%
Calithera Biosciences Inc. -245.53% -31.7% -27.2%

Risk & Volatility

uniQure N.V. has a beta of 1.07 and its 7.00% more volatile than S&P 500. Calithera Biosciences Inc.’s 131.00% more volatile than S&P 500 which is a result of the 2.31 beta.


The Current Ratio and a Quick Ratio of uniQure N.V. are 7.6 and 7.6. Competitively, Calithera Biosciences Inc. has 13.7 and 13.7 for Current and Quick Ratio. Calithera Biosciences Inc.’s better ability to pay short and long-term obligations than uniQure N.V.

Analyst Ratings

uniQure N.V. and Calithera Biosciences Inc. Ratings and Recommendations are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
uniQure N.V. 0 0 8 3.00
Calithera Biosciences Inc. 0 0 0 0.00

uniQure N.V.’s upside potential is 35.16% at a $78.5 consensus price target.

Institutional & Insider Ownership

uniQure N.V. and Calithera Biosciences Inc. has shares held by institutional investors as follows: 78.9% and 69.8%. Insiders held 2.2% of uniQure N.V. shares. Competitively, Calithera Biosciences Inc. has 1.35% of it’s share held by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
uniQure N.V. 6.3% 73.4% 107.66% 40.7% 137.94% 106.07%
Calithera Biosciences Inc. -0.87% 27.8% 17.53% 9.62% -26.45% 42.14%

For the past year uniQure N.V. was more bullish than Calithera Biosciences Inc.


Calithera Biosciences Inc. beats on 8 of the 11 factors uniQure N.V.

uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The companyÂ’s principle programs include AMT-060, a gene therapy that has completed Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical product candidate for the treatment of congestive heart failure; and AMT-130 for the treatment of huntington's disease. It also provides Glybera, a gene therapy product that has approved for the treatment of patients with lipoprotein lipase deficiency. The company has collaboration and license agreements with Bristol-Myers Squibb Company, 4D Molecular Therapeutics, Synpromics, and Chiesi Farmaceutici S.p.A. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase Ib/2 clinical trials for the treatment of solid tumors. The company has a license agreement with Mars, Inc. to develop and commercialize SymbioscienceÂ’s portfolio of arginase inhibitors for use in human healthcare; and license and research agreement with High Point Pharmaceuticals, LLC and TransTech Pharma LLC to develop and commercialize hexokinase II inhibitors. In addition, it has clinical trial collaboration with Bristol-Myers Squibb Company to evaluate Opdivo (nivolumab) in combination with CB-839 in clear cell renal cell carcinoma. The company has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of CB-1158, a small molecule arginase inhibitor for the treatment of hematology and oncology. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.